Declan G. Murphy

Last updated

Declan G. Murphy

FRACS, FRCS
Born
Portumna, County Galway
Education NUI Galway
Occupation Surgeon
Medical career
Profession Urological surgeon
FieldGenitourinary oncology
Institutions
ResearchRobotic surgery for prostate cancer
Website Official website

Declan G. Murphy, FRACS, FRCS, is a urologist, director of the unit for genitourinary oncology and robotic surgery at the Peter MacCallum Cancer Centre in Melbourne, Australia, professor at the Sir Peter MacCallum Department of Oncology at the University of Melbourne, and associate editor of the British Journal of Urology International . In 2010 he introduced robotic surgery for urology to the public sector health services in Victoria, Australia.

Contents

Murphy's early career began in Dublin before taking up training in the specialty of urology in England. After completing a fellowship in laparoscopic and robotic surgery in Melbourne, he returned to London and was appointed consultant urologist at Guy's and St Thomas' Hospital in 2009. The following year he moved to Australia and took up a consultant post at the Peter MacCallum Cancer Centre.

He is a regular blogger on topics pertaining to men's health. In May 2018, his tweet became a popular meme after he demonstrated the use of the da Vinci robot in performing surgery on a grape, with the purpose of introducing children to the topic.

In 2019 he was appointed full professor. The following year he was senior author on the team that published their results on an imaging technique that uses gallium-labelled prostate specific membrane antigen in a PET/CT scanner (PSMA PET-CT), for detecting the early spread of prostate cancer.

Early life and education

Declan Murphy is from Portumna, County Galway, in the West of Ireland, where his father and sister are general practitioners. In 1996 Murphy graduated in medicine from NUI Galway and subsequently completed early medical training at the University Hospital Galway, Mullingar Hospital, Meath & Adelaide Hospital, Our Lady of Lourdes Hospital and St. James's Hospital, Dublin, before moving to England to take up training in the specialty of urology, first in Brighton, Worthing and Redhill, and then at Guy's and St Thomas' NHS Foundation Trust, London. [1] [2]

Career

In 2006 he was awarded the FRCS Royal College of Surgeons in Ireland Urol and subsequently completed a one-year fellowship under Anthony J. Costello in laparoscopic and robotic urology in Melbourne, which changed his opinion of operating on the prostate using a robot. [1] [2] Between January 2009 and December 2009, he was consultant in urology at Guy's and St Thomas', London. [2] He is a reviewer and is on the editorial board for urology related publications including European Urology , Nature Reviews Urology, The Journal of Urology , the BJU International , Prostate Cancer and Prostatic Diseases, and the Journal of Sexual Medicine . [3] [4]

Robotic surgery

In 2010 he returned to Melbourne and introduced robotic surgery for urology to the public sector health services in Victoria, [5] when he took up a consultant post at the Peter MacCallum Cancer Centre, where he later became director of robotic surgery. In 2011 he was awarded the FRACS. [2] [3] [6]

In 2015 he performed a live robotic prostatectomy which was broadcast as part of the "World Robotic Surgery Event". [7] By 2019 he had performed near 2000 robotic prostatectomies. [5]

Social media

He is a regular blogger on topics pertaining to men's health. [8] His blog on skills of a surgeon in robotics in 2016 titled "It's not about the machine, stupid", [9] won the 2018 British Journal of Urology International's social media award for most commented upon blog. [4]

In May 2018, to demonstrate to children how robotic procedures were carried out with precision, he successfully performed surgery on a grape using a da Vinci robot. A few months later, his twitter feed was picked up and the resulting social media attention led the story to become a popular meme. [10]

Prostate cancer detection

He has been an advocate of early PSA testing, and has argued that it saves lives through early detection of prostate cancer. [11] In 2013 he led the Melbourne Consensus Statement on early detection of prostate cancer. [12] In 2018 he revealed in the Medical Journal of Australia , his findings that three-quarters of men with low-grade prostate cancer who should have been getting regular checks, did not comply with surveillance recommendations. [13]

In 2020, the year after he was appointed full professor, he was senior author on the team that published their results on an imaging technique that uses gallium-labelled prostate specific membrane antigen in a PET/CT scanner (PSMA PET-CT), for detecting the early spread of prostate cancer. [14] [15] [16] [17]

COVID-19

During the COVID-19 pandemic in 2020, Murphy chaired the Victorian COVID-19 Cancer Network and highlighted concerns about decreasing diagnoses of prostate cancer due to social distancing measures. [18] [19]

Personal and family

He is married to Lisa and they have two sons. [20]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Prostatectomy</span> Surgical removal of all or part of the prostate gland

Prostatectomy is the surgical removal of all or part of the prostate gland. This operation is done for benign conditions that cause urinary retention, as well as for prostate cancer and for other cancers of the pelvis.

<span class="mw-page-title-main">Robot-assisted surgery</span> Surgical procedure

Robot-assisted surgery or robotic surgery are any types of surgical procedures that are performed using robotic systems. Robotically assisted surgery was developed to try to overcome the limitations of pre-existing minimally-invasive surgical procedures and to enhance the capabilities of surgeons performing open surgery.

<span class="mw-page-title-main">Radical perineal prostatectomy</span>

Radical perineal prostatectomy is a surgical procedure wherein the entire prostate gland is removed through an incision in the area between the anus and the scrotum (perineum).

A gallium scan is a type of nuclear medicine test that uses either a gallium-67 (67Ga) or gallium-68 (68Ga) radiopharmaceutical to obtain images of a specific type of tissue, or disease state of tissue. Gallium salts like gallium citrate and gallium nitrate may be used. The form of salt is not important, since it is the freely dissolved gallium ion Ga3+ which is active. Both 67Ga and 68Ga salts have similar uptake mechanisms. Gallium can also be used in other forms, for example 68Ga-PSMA is used for cancer imaging. The gamma emission of gallium-67 is imaged by a gamma camera, while the positron emission of gallium-68 is imaged by positron emission tomography (PET).

<span class="mw-page-title-main">Glutamate carboxypeptidase II</span> Enzyme

Glutamate carboxypeptidase II (GCPII), also known as N-acetyl-L-aspartyl-L-glutamate peptidase I, NAAG peptidase, or prostate-specific membrane antigen (PSMA) is an enzyme that in humans is encoded by the FOLH1 gene. Human GCPII contains 750 amino acids and weighs approximately 84 kDa.

<span class="mw-page-title-main">Laparoscopic radical prostatectomy</span>

Laparoscopic radical prostatectomy (LRP) is a form of radical prostatectomy, an operation for prostate cancer. Contrasted with the original open form of the surgery, it does not make a large incision but instead uses fiber optics and miniaturization.

<span class="mw-page-title-main">Mani Menon</span>

Mani Menon, born 9 July 1948 in Trichur, India, is an American surgeon whose work has helped to lay the foundation for modern Robotic Cancer Surgery. He is the founding director and the Raj and Padma Vattikuti Distinguished Chair of the Vattikuti Urology Institute at the Henry Ford Hospital in Detroit, MI, where he established the first cancer-oriented robotics program in the world. Menon is widely regarded for his role in the development of robotic surgery techniques for the treatment of patients with prostate, kidney, and bladder cancers, as well as for the development of robotic kidney transplantation.
Menon is the recipient of the Gold Cystoscope award, Hugh Hampton Young award, the Keyes Medal, the prestigious B.C. Roy award.

<span class="mw-page-title-main">Ashutosh Tewari</span> American urologist, oncologist

Ashutosh K. Tewari is the chairman of urology at the Icahn School of Medicine at Mount Sinai Hospital in New York City. He is a board certified American urologist, oncologist, and principal investigator. Before moving to the Icahn School of Medicine in 2013, he was the founding director of both the Center for Prostate Cancer at Weill Cornell Medical College and the LeFrak Center for Robotic Surgery at NewYork–Presbyterian Hospital. Dr. Tewari was the Ronald P. Lynch endowed Chair of Urologic Oncology and the hospital's Director of Robotic Prostatectomy, treating patients with prostate, urinary bladder and other urological cancers. He is the current President of the Society for Urologic Robotic Surgeons (SURS) and the Committee Chair of the Prostate Program. Dr. Tewari is a world leading urological surgeon, and has performed over 10,000 robotically assisted procedures using the da Vinci Surgical System. Academically, he is recognized as a world-renowned expert on urologic oncology with over 250 peer reviewed published papers to his credit; he is on such lists as America's Top Doctors, New York Magazine's Best Doctors, and Who's Who in the World. In 2012, he was given the American Urological Association Gold Cystoscope Award for "outstanding contributions to the field of urologic oncology, most notably the treatment of prostate cancer and the development of novel techniques to improve the outcomes of robotic prostatectomy."

Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship based interventions. These interventions are focused on five domains including: physical symptoms, psychological symptoms, surveillance, health promotion and care coordination. However, a published review has found only high levels of evidence for interventions that target physical and psychological symptom management and health promotion, with no reviews of interventions for either care coordination or surveillance. The favored treatment option depends on the stage of the disease, the Gleason score, and the PSA level. Other important factors include the man's age, his general health, and his feelings about potential treatments and their possible side-effects. Because all treatments can have significant side-effects, such as erectile dysfunction and urinary incontinence, treatment discussions often focus on balancing the goals of therapy with the risks of lifestyle alterations.

<span class="mw-page-title-main">Michael Palese</span>

Dr. Michael A. Palese, is an American urologist specializing in robotic, laparoscopic and endoscopic surgery, with a special emphasis on robotic surgeries relating to kidney cancer and kidney stone disease.

<span class="mw-page-title-main">Roger Kirby</span> British surgeon

Roger Sinclair Kirby FRCS(Urol), FEBU is a British retired prostate surgeon and professor of urology, researcher, writer on men's health and prostate disease, founding editor of the journal Prostate Cancer and Prostatic Diseases and Trends in Urology and Men's Health and a fundraiser for prostate disease charities, best known for his use of the da Vinci surgical robot for laparoscopic prostatectomy in the treatment of prostate cancer. He is a co-founder and president of the charity The Urology Foundation (TUF), vice-president of the charity Prostate Cancer UK, trustee of the King Edward VII's Hospital and as of 2020 is president of the Royal Society of Medicine (RSM), London.

<span class="mw-page-title-main">Michael Stifelman</span> American physician and urologist

Michael D. Stifelman Michael D. Stifelman, M.D., is Chair of Urology at Hackensack University Medical Center, Director of Robotic Surgery at Hackensack Meridian Health, and Professor and Inaugural Chair of Urology at Hackensack Meridian School of Medicine.

<span class="mw-page-title-main">Prokar Dasgupta</span>

Prokar Dasgupta is an Indian-born British surgeon and academic who is professor of surgery at the surgical academy at King's Health Partners, London, UK. Since 2002, he has been consultant urologist to Guy's Hospital, and in 2009 became the first professor of robotic surgery and urology at King's, and subsequently the chairman of the King's College-Vattikuti Institute of Robotic Surgery.

Kevin M. Slawin is an American physician and the founder of Bellicum Pharmaceuticals and the Vanguard Urologic Institute at Memorial Hermann Medical Group. He was also the Director of Urology at Memorial Hermann Hospital. Slawin specializes in the diagnosis and treatment of urologic cancers and robotic surgery. He is also possesses patents related to the advancement of prostate cancer diagnosis, staging and treatment and to the cellular immunotherapy of cancer.

<span class="mw-page-title-main">Vipul Patel</span>

Vipul R. Patel, FACS is the founder and Medical Director of the Florida Hospital Global Robotics Institute, founder and Vice President of the Society of Robotic Surgery, and founder and Editor Emeritus of The Journal of Robotic Surgery. He is board certified by the American Urological Association and specializes in robotic surgery for prostate cancer. As of June, 2023 he performed his 17,000th robotic-assisted prostatectomy. The large volume of prostatectomies he has performed has enabled him to amass a large amount of statistical evidence regarding the efficacy of robotic techniques which has been used in developing and refining techniques. Patel credits the use of robotic assisted surgery with helping surgeons achieve better surgical outcomes with the "trifecta" of cancer control, continence and sexual function. In the course of his career Patel has led and participated in studies that have resulted in developing improved outcomes for robotic surgery and urologic treatment.

A PSMA scan is a nuclear medicine imaging technique used in the diagnosis and staging of prostate cancer. It is carried out by injection of a radiopharmaceutical with a positron or gamma emitting radionuclide and a prostate-specific membrane antigen (PSMA) targeting ligand. After injection, imaging of positron emitters such as gallium-68 (68Ga), copper-64 (64Cu), and fluorine-18 (18F) is carried out with a positron emission tomography (PET) scanner. For gamma emitters such as technetium-99m (99mTc) and indium-111 (111In) single-photon emission computed tomography (SPECT) imaging is performed with a gamma camera.

<span class="mw-page-title-main">Ben Challacombe</span> British urological surgeon

Benjamin James Challacombe is a British consultant urological surgeon at Guy's & St Thomas' Hospitals, and at King’s College London, who specialises in the treatment of kidney and prostatic disease using robotic surgery. In 2005, he was part of the team that published the results of a randomised controlled trial of human versus telerobotics in the field of urology and renal transplant, one of the first of its kind.

Anthony James Costello, FRACS, FRCSI, is an Australian urologist. He served as head of the department of urology at the Royal Melbourne Hospital, Australia. He established the first robotic prostate cancer surgery programme in Australia and published the first series of men who had laser surgery for benign prostate enlargements.

<span class="mw-page-title-main">Piflufolastat F-18</span> Chemical compound

Piflufolastat F-18, sold under the brand name Pylarify among others, is a radioactive diagnostic agent used for positron emission tomography (PET) imaging. It is given by intravenous injection.

Lutetium (<sup>177</sup>Lu) vipivotide tetraxetan Radiopharmaceutical medication

Lutetium (177Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Lutetium (177Lu) vipivotide tetraxetan is a targeted radioligand therapy.

References

  1. 1 2 "Upwardly mobile life in a land down under". Irish Medical Times. 13 September 2011. Archived from the original on 21 November 2017. Retrieved 21 September 2020.
  2. 1 2 3 4 Declan G Murphy - "Curriculum Vitae", June 2020
  3. 1 2 "APCRC-Q Seminar Series — Australian Prostate Cancer Research Centre - Queensland". www.australianprostatecentre.org. 2011. Retrieved 21 September 2020.
  4. 1 2 "Declan Murphy Archives". BJUI. Retrieved 27 September 2020.
  5. 1 2 Fisher, Brian (16 April 2019). "Navigate Prostate | News - Declan Murphy, Site Investigator at Peter Mac". www.news.navigateprostate.com. Retrieved 20 September 2020.
  6. ↑ Nogrady, Bianca (December 2015). "Q&A: Declan Murphy". Nature. 528 (7582): S132–S133. Bibcode:2015Natur.528S.132N. doi: 10.1038/528S132a . ISSN   1476-4687. PMID   26672787. S2CID   4467363.
  7. ↑ "Experts stage live 24-hour robotic-assisted surgery event on four continents". www.abc.net.au. 16 February 2015. Retrieved 15 October 2020.
  8. ↑ "Surgical Grand Rounds - Professor Declan Murphy — Nuffield Department of Surgical Sciences". www.nds.ox.ac.uk. 23 November 2018. Retrieved 27 September 2020.
  9. ↑ Biers, Suzanne; Armenakas, Noel; Lamb, Alastair; Mark, Stephen; Reynard, John; Sullivan, Sullivan; Turner, Kevin; Turney, Ben, eds. (2020). "Laparoscopic and Urological Robotic Surgery". Urological Surgery. Oxford University Press. pp. 280–283. ISBN   978-0-19-108257-3.
  10. ↑ Nagesh, Ashitha (26 November 2018). "New meme alert: Did you know they did surgery on a grape?". BBC Three. Retrieved 21 September 2020.
  11. ↑ Medew, Julia (31 July 2012). "Cancer specialist slams 'prostate spin for cash'". The Sydney Morning Herald. Retrieved 20 September 2020.
  12. ↑ Basto, M.; Goggins, A.; Loeb, S. (1 January 2013). "Updates in the care and management of prostate cancer: highlights from the 2013 prostate cancer world congress, august 6-10, 2013, Melbourne, Australia". Reviews in Urology. 15 (4): 185–187. PMC   3922323 . PMID   24659915.
  13. ↑ Margo, Jill (28 May 2018). "Prostate cancer management has structural weakness that may hit thousands of men". Australian Financial Review. Retrieved 16 October 2020.
  14. ↑ Osterweil, Neil (24 March 2020). "Improved Imaging for Prostate Cancer With PSMA PET-CT" . Medscape. Retrieved 21 September 2020.
  15. ↑ Moore, Caroline (11 April 2020). "Prostate-specific membrane antigen PET-CT before radical treatment" . The Lancet. 395 (10231): 1170–1172. doi:10.1016/S0140-6736(20)30527-4. ISSN   0140-6736. PMID   32209450. S2CID   214609489.
  16. ↑ "The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer". EurekAlert!. Archived from the original on 22 September 2020. Retrieved 21 September 2020.
  17. ↑ Shannon, June (12 May 2015). "'Game-changer' emerges". Irish Medical Times. Archived from the original on 22 September 2020. Retrieved 21 September 2020.
  18. ↑ Morgans, Alicia; Murphy, Declan (12 May 2020), The Impact of the COVID-19 Pandemic in Australia - Declan Murphy, UroToday, retrieved 21 September 2020
  19. ↑ Cunningham, Melissa (26 April 2020). "Fears seriously ill people going unchecked as cancer referrals plummet". The Sydney Morning Herald. Retrieved 14 October 2020.
  20. ↑ "Professor Declan Murphy". Professor Declan Murphy. Archived from the original on 21 March 2020. Retrieved 12 October 2020.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.